NBIX

Business Context and Reporting Period

Company: Neurocrine Biosciences, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 2005
Business Overview: Neurocrine is a biopharmaceutical company discovering and developing drugs for neurological and endocrine-related diseases. The company has no approved products and generates revenue primarily through strategic collaborations, milestone payments, and license fees. Its lead drug candidate, indiplon (for insomnia), had its New Drug Application (NDA) accepted for review by the FDA in June 2005.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Total revenue increased 41% to $45.0 million for the six months ended June 30, 2005, compared to $32.0 million in the prior year. This was driven primarily by a $20.0 million milestone payment from Pfizer related to the FDA acceptance of the indiplon capsule NDA and $6.0 million in sales force allowance revenue.
• Expense Increases: Operating expenses rose to $70.6 million from $60.1 million. Research and Development (R&D) expenses increased to $55.2 million due to higher external development costs for non-indiplon programs (GnRH, urocortin 2, multiple sclerosis). Sales, General, and Administrative (SG&A) expenses increased to $15.4 million, largely due to the build-out of a 200-person sales force.
• Cash Flow: Net cash used in operating activities decreased to $53.5 million from $64.0 million in the prior year, primarily due to a smaller decrease in accounts payable. Net cash provided by investing activities turned positive ($41.9 million) compared to a use of $45.3 million in 2004, driven by the absence of a $50.0 million royalty prepayment made in 2004 and reduced capital expenditures following the completion of headquarters construction.

Guidance, Outlook, and Risks

• Outlook: Management expects to incur net losses throughout 2005. A $50.0 million milestone payment from Pfizer is expected in the third quarter of 2005 upon FDA acceptance of the indiplon tablet NDA. SG&A expenses are expected to remain elevated due to the newly established sales force.
• Liquidity: The company believes existing capital resources ($243.3 million in cash and short-term investments) and future collaboration payments will satisfy funding requirements for at least the next 12 months. However, additional funding may be required for future R&D and commercialization.
• Accounting Changes: The company is preparing for the adoption of SFAS No. 123R (Share-Based Payment) in fiscal 2006, which will require expensing stock options at fair value, likely increasing reported net losses significantly.
• Key Risks:
  • Regulatory approval delays or rejection of the indiplon NDAs.
  • Dependence on Pfizer for funding, commercialization, and co-promotion of indiplon.
  • Failure of clinical trials for other pipeline candidates.
  • Need for additional capital if milestones or collaboration funding are insufficient.

Investor Verification Checklist

• Indiplon NDA Status: Verify the FDA's review timeline and potential approval dates for both the capsule and tablet formulations of indiplon.
• Pfizer Collaboration Terms: Review the specific conditions for the anticipated $50.0 million third-quarter milestone and the long-term revenue structure of the sales force allowance.
• Capital Runway: Assess the sufficiency of the $243.3 million liquidity position against projected R&D burn rates for non-indiplon programs.
• Stock-Based Compensation Impact: Monitor the company's analysis of the impact of SFAS No. 123R adoption on future earnings per share.
• Debt Obligations: Review the terms of the $62.6 million total debt, including interest rates and maturity schedules.